Ascendis Pharma A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ascendis Pharma A/S
The European Medicines Agency had a busy time at its meeting last week. It gave the green light to 11 products, four of which are for rare diseases including ANCA-associated vasculitis, and to a range of treatments for conditions as diverse as non-small cell lung cancer, smallpox, migraine, COPD, COVID-19 and obesity.
The US FDA has extended the user fee date by three months for the partners’ BCMA-targeting CAR-T therapy but its first-to-market rival is facing manufacturing challenges that limit access to treatment.
Renaissance Capital expects an initial public offering surge in September; Biomedtracker data show financings for COVID-19 programs fell from Q1 to Q2; Revelation will merge with a special purpose acquisition corporation; Ascendis netted $379.3m in a follow-on offering; and Disc Medicine raised $90m in venture capital.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Controlled Release
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Visen Pharmaceuticals